These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23536483)

  • 41. Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen.
    Santos SA; Uriel AJ; Park JS; Lucas J; Carriero D; Jaffe D; Dieterich DT
    Eur J Gastroenterol Hepatol; 2006 Dec; 18(12):1247-53. PubMed ID: 17099372
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus.
    Herreros de Tejada Echanojáuregui A; Moreno Planas JM; Rubio González E; Portero Azorin F; López Monclús J; Revilla Negro J; Lucena de la Poza JL; Sánchez Turrión V; Barrios Peinado C; Cuervas-Mons Martínez V
    Transplant Proc; 2005 Apr; 37(3):1507-8. PubMed ID: 15866657
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adefovir-lamivudine combination therapy and hepatitis B viral kinetics.
    Mutimer D
    J Hepatol; 2005 Aug; 43(2):200-2. PubMed ID: 15975684
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection.
    Gornals JB; Casanovas T; Sabidó M; Baliellas C; Casanovas A; Cañas C; Serrano T; Verdura B; Chahri N; Gil-Vernet S; Figueras J
    Transplant Proc; 2005 Nov; 37(9):3957-9. PubMed ID: 16386595
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The clinical study of adding on adefovir dipivoxil to treat for lamivudine resistant patients with chronic hepatitis B].
    DING JG; SUN QF; FU RQ; WU YH; HONG L
    Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):387-8. PubMed ID: 19497209
    [No Abstract]   [Full Text] [Related]  

  • 46. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
    Lampertico P; Viganò M; Manenti E; Iavarone M; Lunghi G; Colombo M
    Hepatology; 2005 Dec; 42(6):1414-9. PubMed ID: 16317671
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL;
    Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951
    [TBL] [Abstract][Full Text] [Related]  

  • 48. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
    Reddy KR; Beavers KL; Hammond SP; Lim JK; Falck-Ytter YT;
    Gastroenterology; 2015 Jan; 148(1):215-9; quiz e16-7. PubMed ID: 25447850
    [No Abstract]   [Full Text] [Related]  

  • 49. De Novo Hepatitis B Infection From Hepatitis B Core Antibody-Positive Donors During Hepatitis B Immunoglobulin Prophylaxis.
    Shin M; Chang SH
    Exp Clin Transplant; 2016 Feb; 14(1):106-8. PubMed ID: 26325029
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: is adefovir dipivoxil the answer?
    Thio CL
    J Hepatol; 2006 Jan; 44(1):1-3. PubMed ID: 16293338
    [No Abstract]   [Full Text] [Related]  

  • 51. Successful Management of De Novo Acute Hepatitis B Virus Infection With Entecavir in a Living-Donor Liver Transplant Patient.
    Akbulut S; Harputluoglu M; Yilmaz S
    Exp Clin Transplant; 2018 Oct; 16(5):635-637. PubMed ID: 29790455
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
    Svarovskaia ES; Curtis M; Zhu Y; Borroto-Esoda K; Miller MD; Berg T; Lavocat F; Zoulim F; Kitrinos KM
    J Viral Hepat; 2013 Feb; 20(2):131-40. PubMed ID: 23301548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: a randomized, double-blind, multicenter clinical study].
    Zhao H; Li J; Zhang YX; Chen XY; Wang L; Tang XP; Lei CL; Si CW
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):282-4. PubMed ID: 17971947
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results.
    Taltavull TC; Chahri N; Verdura B; Gornals J; Lopez C; Casanova A; Cañas C; Figueras J; Casais LA
    Transpl Int; 2005 Jul; 18(7):879-83. PubMed ID: 15948869
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
    Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
    Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination.
    Bárcena Marugán R; García-Hoz F; Vázquez Romero M; Nash R; Mateos M; González Alonso R; García González M; García Plaza A
    Am J Gastroenterol; 2002 Sep; 97(9):2398-401. PubMed ID: 12358263
    [TBL] [Abstract][Full Text] [Related]  

  • 57. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
    Perrillo RP; Gish R; Falck-Ytter YT
    Gastroenterology; 2015 Jan; 148(1):221-244.e3. PubMed ID: 25447852
    [No Abstract]   [Full Text] [Related]  

  • 58. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transmission of hepatitis B infection from hepatitis B core antibody--positive livers: background and prevention.
    Rizzetto M
    Liver Transpl; 2001 Jun; 7(6):518-20. PubMed ID: 11443580
    [No Abstract]   [Full Text] [Related]  

  • 60. Acute liver failure resulting from discontinuation of nucleoside analogues in chronic hepatitis B patients: a report of two cases.
    Wang J; Wang M; Huang Y
    Scand J Infect Dis; 2013 Feb; 45(2):158-60. PubMed ID: 22830672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.